Navigation Links
Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
Date:11/20/2013

ogy also has potential for other areas of vascular surgery, including replacement of infected synthetic grafts."

"We are very encouraged by the Humacyte investigational bioengineered vessel's performance in end-stage renal disease patients," said Dr. Lawson. "Tremendous medical need exists for vascular access grafts in patients with ESRD who require dialysis. Based on this interim data and other ongoing research, we believe that the investigational bioengineered vessel has potential to meet this significant need."

Need to Overcome Limitations of PTFE Grafts

Currently available synthetic vessels made from polytetrafluoroethylene (PTFE) are subject to many complications and about half fail within a year, requiring replacement surgery. PTFE vessels tend to become blocked (have low patency rates), have high rates of stenosis (an abnormal narrowing in a blood vessel that can be associated with hemodialysis), and high intervention rates.

"We continue to make significant progress in our research and development program with the Humacyte investigational bioengineered blood vessel," said Laura E. Niklason, M.D., Ph.D., professor and vice chair of Anesthesia, professor of Biomedical Engineering, Yale University, and founder, Humacyte. "With our current interim study data, all of the Humacyte vessels have remained open to blood flow, with 20 out of the 28 implants requiring no intervention to date. We are grateful to patients, investigators, regulators and the broader vascular community for their ongoing collaboration and support in advancing this science."

Unmet Medical Need in Chronic Kidney Disease

The Humacyte investigational technology is being developed with the goal of pursuing approval for use in patients with chronic kidney disease, a major global health problem affecting 26 million Americans[1] and around 40 million people in the European Union (EU).[2] Individuals who prog
'/>"/>

SOURCE Humacyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
3. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
4. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
5. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
9. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
10. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
11. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets ... Target High Unmet Need in Newly ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... DIEGO , Aug. 28, 2014 Telik, ... development company that merged with MabVax Therapeutics, Inc. ... made significant progress related to the development of ... antibody was recovered using the Company,s internally developed ... the potential for multiple antibody based therapeutic and ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... A surgeon at the St. Francis Heart Center ... to rebuild their own cardiovascular tissue. , , (Logo: ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090708/DE43062LOGO-b ) ... Extracellular Matrix (ECM)(TM) to modify and repair cardiac structures, allowing ...
... Calif., July 7 Amgen (Nasdaq: AMGN ... trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the ... breast cancer met its primary and secondary endpoints and ... demonstrated for both delaying the time to the first ...
Cached Medicine Technology:St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures 2St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:8/29/2014)... Astoria, New York, (PRWEB) August 29, 2014 ... a degenerative condition that damages the motor neurons in the ... and more of the nerve cells controlling movement are harmed, ... functions. Eventually this leads to death. , ALS is ... and 70, and as many as 30,000 Americans have the ...
(Date:8/29/2014)... Top10BestSEOHosting.com today compares many professional ... announces that Bluehost ( http://www.bluehost.com/track/seohosts ), Arvixe, and ... for webmasters who want to buy high quality ... at affordable rates. , Bluehost is also a ... its features is that Bluehost provides quality hosting ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 According ... a lawsuit against Pfizer Inc., Greenstone LLC and Pfizer ... with congenital birth defects as a result of ... defect lawsuit was filed in St. Clair County Circuit ... to the lawsuit, the defendant companies allegedly concealed the ...
(Date:8/29/2014)... Visiting Nurse Association of Northern New ... delivering comfort and companionship to terminally-ill patients and their ... continues to grow and their needs expand, the VNA ... The next Hospice Training Program will be offered on ... P.M. at VNA’s headquarters, 175 South Street in Morristown. ...
(Date:8/29/2014)... The Winscribe Board of Directors today announced the ... from 1st September 2014. Allen previously held the position ... time of growth, there is no better person to ... Founder and Chairman of the Board. “Allen is a ... management experience gained in New Zealand, Europe and the ...
Breaking Medicine News(10 mins):Health News:Charity Event to Raise Awareness and Donations for the ALS Foundation 2Health News:Top10BestSEOHosting.com: Bluehost, Arvixe, and Hostgator Are the Best Windows Web Hosting from the USA in 2014 2Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:VNA Offers Rewarding Hospice Volunteer Opportunity 2Health News:VNA Offers Rewarding Hospice Volunteer Opportunity 3Health News:Winscribe Names Greg Allen as CEO 2
... Blue Cross and Blue Shield of Georgia (BCBSGA) ... reached agreement on a three-year contract, effective August ... members can continue to access Piedmont Healthcare as ... physicians, Piedmont Hospital in Atlanta, Piedmont Fayette Hospital ...
... North America,s largest annual interdisciplinary academic conference kicks off in ... Carleton University to present and debate research from across the ... will be held this Friday at 10:30 a.m. in the ... of what to expect. , Nathalie Des Rosiers, president of ...
... By combining the expertise of its ... (BEZ.L) has developed enhanced management liability coverage ... of healthcare organizations, including hospitals, long term ... is an adaptation of Beazley,s successful BeazleyOne ...
... calls to consider reducing the legal drinking age, a new University of ... births among young people. , ... Athens, Ga. (Vocus) May 21, 2009 ... new University of Georgia study finds that lower drinking ages ...
... May 21 For the second year in a ... to donate blood through the Red Cross by joining ... Red Cross Racing is a program designed to increase ... they donate. Participants of this program can get points for ...
... shows droplets rubbed into skin prevented infections , , THURSDAY, ... rubbed into the skin appear to protect against ear ... , If this approach proves effective in humans, it ... infections, the researchers noted. , Three groups of chinchillas ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Georgia and Piedmont Healthcare Announce Contract Renewal 2Health News:Thousands of Canada's best minds converge at Congress 2009 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 2Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:Pediatric Ear Infection Vaccine Shows Promise 2
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
... designed for use with our CARTO EP ... catheter houses a Biosense Webster sensor at ... time, exact location points from within the ... The NAVI-STAR electro-anatomical navigation catheter is used ...
... Tricuspid Mapping. Biosense Webster offers a complete ... in the atrium. The HALO XP 20-pole ... and mapping around the tricuspid annulus. The ... distal tip (on P15-FS/0 permit pacing in ...
... Webster is the source for a complete ... left-sided mapping - all with the quality, ... expect from the leader in catheter technology. ... specifically designed and constructed to help minimize ...
Medicine Products: